argenex SE $ARGX Shares Acquired by Voya Investment Management LLC

by · The Cerbat Gem

Voya Investment Management LLC grew its stake in shares of argenex SE (NASDAQ:ARGX – Free Report) by 36.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,610 shares of the company’s stock after acquiring an additional 5,755 shares during the quarter. Voya Investment Management LLC’s holdings in argenex were worth $15,939,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Millennium Management LLC raised its stake in argenex by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after purchasing an additional 204,180 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after acquiring an additional 158,476 shares during the last quarter. Franklin Resources Inc. increased its stake in argenex by 103.9% during the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after acquiring an additional 142,606 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of argenex by 1,203.4% in the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock worth $78,931,000 after purchasing an additional 123,127 shares during the period. Finally, Braidwell LP lifted its stake in shares of argenex by 99.2% in the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock valued at $95,201,000 after purchasing an additional 80,083 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Down 0.3%

Shares of NASDAQ ARGX opened at $852.04 on Tuesday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The business has a 50 day moving average price of $869.93 and a two-hundred day moving average price of $729.81. The firm has a market cap of $52.46 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 0.89 and a beta of 0.36.

argenex (NASDAQ:ARGX – Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. On average, analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ARGX. Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Jefferies Financial Group set a $818.00 price target on shares of argenex and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Morgan Stanley raised their price objective on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Bank of America increased their target price on argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company boosted their price target on argenex from $1,095.00 to $1,316.00 and gave the stock an “overweight” rating in a research report on Thursday, December 11th. Nineteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, argenex has an average rating of “Moderate Buy” and an average target price of $982.33.

View Our Latest Stock Analysis on argenex

argenex Company Profile

(Free Report)

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

Further Reading